Wan Hongping, Zhong Xinyi, Yang Shinong, Deng Jiarong, Song Xu, Liu Yong, Li Yuanfeng, Yin Zhongqiong, Zhao Xinghong
Center for Sustainable Antimicrobials, Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, 611130, China.
Center for Infectious Diseases Control (CIDC), Sichuan Agricultural University, Chengdu, 611130, China.
Adv Sci (Weinh). 2025 Jan;12(3):e2411753. doi: 10.1002/advs.202411753. Epub 2024 Nov 25.
The rise of antibiotic resistance, coupled with a dwindling antibiotic pipeline, presents a significant threat to public health. Consequently, there is an urgent need for novel therapeutics targeting antibiotic-resistant pathogens. Nisin, a promising peptide antibiotic, exhibits potent bactericidal activity through a mechanism distinct from that of clinically used antibiotics. However, its cationic nature leads to hemolysis and cytotoxicity, which has limited its clinical application. Here, nanodelivery systems have been developed by mimicking the mechanisms bacteriophages use to deliver their genomes to host bacteria. These systems utilize bacteriophage receptor-binding proteins conjugated to loading modules, enabling efficient targeting of bacterial pathogens. Peptide antibiotics are loaded via dynamic covalent bonds, allowing for infection microenvironment-responsive payload release. These nanodelivery systems demonstrate remarkable specificity against target pathogens and effectively localize to bacteria-infected lungs in vivo. Notably, they significantly reduce the acute toxicity of nisin, rendering it suitable for intravenous administration. Additionally, these bacteriophage-mimicking nanomedicines exhibit excellent therapeutic efficacy in a mouse model of MRSA-induced pneumonia. The facile synthesis, potent antimicrobial performance, and favorable biocompatibility of these nanomedicines highlight their potential as alternative therapeutics for combating antibiotic-resistant pathogens. This study underscores the effectiveness of bacteriophage mimicry as a strategy for transforming peptide antibiotics into viable therapeutics.
抗生素耐药性的上升,再加上抗生素研发线的缩减,对公众健康构成了重大威胁。因此,迫切需要针对耐药病原体的新型疗法。乳酸链球菌素是一种很有前景的肽类抗生素,其杀菌活性机制与临床使用的抗生素不同。然而,其阳离子性质会导致溶血和细胞毒性,这限制了它的临床应用。在此,通过模仿噬菌体将其基因组传递给宿主细菌的机制,开发了纳米递送系统。这些系统利用与装载模块偶联的噬菌体受体结合蛋白,实现对细菌病原体的有效靶向。肽类抗生素通过动态共价键加载,使载荷能够在感染微环境中响应释放。这些纳米递送系统对靶病原体表现出显著的特异性,并能在体内有效定位于细菌感染的肺部。值得注意的是,它们显著降低了乳酸链球菌素的急性毒性,使其适合静脉给药。此外,这些模仿噬菌体的纳米药物在耐甲氧西林金黄色葡萄球菌诱导的肺炎小鼠模型中表现出优异的治疗效果。这些纳米药物的简便合成、强大的抗菌性能和良好的生物相容性突出了它们作为对抗耐药病原体的替代疗法的潜力。这项研究强调了模仿噬菌体作为将肽类抗生素转化为可行疗法的策略的有效性。